🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

114 results for “GT” Clear

  1. SD-809

    Teva Pharma GmbH

    Chorea Associated With Huntington Disease

    phase 3 small molecule completed

    1 trial

  2. SGT-003

    Solid Biosciences

    Duchenne Muscular Dystrophy

    phase 3 gene therapy active

    2 trials

  3. Stereotactic Radiation Therapy

    GT Biopharma

    Brain Metastases

    phase 3 other active

    1 trial

  4. TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg), TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Arterial Hypertension

    phase 3 small molecule active

    1 trial

  5. TRIAMCINOLONE , VANCOMYCIN , CEFAZOLIN , BETAMETHASONE , OMEPRAZOLE , JNJ-74765340, JNJ-74765340, DEXAMETHASONE , CEFUROXIME

    Janssen-Cilag International N.V.

    X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene

    phase 3 small molecule active

    1 trial

  6. Temozolomide

    GT Biopharma

    Glioblastoma

    phase 3 small molecule active

    1 trial

  7. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Chorea, Huntington

    phase 3 small molecule active

    3 trials

  8. Xylocore Medium Strength, bicaVera 4,25 % Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, Xylocore High Strength, PHYSIONEAL 40 Glucose 3,86 % w/v / 38,6 mg/ml, Peritonealdialyselösung, balance 4,25% Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, PHYSIONEAL 35 Glucose 1,36 % w/v / 13,6 mg/ml, Peritonealdialyselösung, FIXIONEAL “35 Glucosio 3,86% p/v/38,6 mg/ml” in sacca Clear-Flex Soluzione per dialisi peritoneale, balance 2,3% Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, PHYSIONEAL

    Lacuna Pharma Pty Ltd

    End-Stage Kidney Disease

    phase 3 small molecule active

    1 trial

  9. [18F]MNI-659

    Pari Pharma GmbH

    Patients with symptomatic and pre-symptomatic Huntington's disease

    phase 3 small molecule active

    1 trial

  10. strengths-based case management

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 3 other completed

    1 trial

  11. A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males with Duchenne Muscular Dystrophy

    Solid Biosciences

    Duchenne muscular dystrophy

    phase 2 other active

    1 trial

  12. ACR16

    Teva Pharma GmbH

    Huntington Disease

    phase 2 small molecule completed

    1 trial

  13. ALN-AGT01 RVR

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule active

    1 trial

  14. AP31969, AP31969, The placebo tablets contain the same excipient as in the active IMP, but without AP31969. All tablet strengths containing AP31969 as well as placebo tablets are visually identical., AP31969, AP31969

    Lacuna Pharma Pty Ltd

    Atrial fibrillation

    phase 2 small molecule active

    1 trial

  15. Active drug: pimavanserin 17mg (2 strength tablets)

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  16. BI 1819479, Placebo, Film-coated tablet, matching in size, weight, colour and shape to BI 1819479 (both unit strengths), BI 1819479

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  17. Bepranemab, Placebo matching and without active substance, Neuraceq 300 MBq/mL solution for injection, (18F) GTP1

    Lacuna Pharma Pty Ltd

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  18. CGT4859

    Cogent Biosciences

    Intrahepatic Cholangiocarcinoma (Icc)

    phase 2 small molecule active

    1 trial

  19. CGT9486

    Cogent Biosciences

    Gastrointestinal Stromal Tumors

    phase 2 small molecule completed

    1 trial

  20. CGT9486, CGT9486

    Cogent Biosciences

    Advanced Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

  21. Cesium-131 brachytherapy

    GT Biopharma

    Recurrent Brain Metastases

    phase 2 other active

    1 trial

  22. Fulvestrant STADA 250 mg injekcinis tirpalas užpildytame švirkšte, Alisertib Enteric-Coated Tablets, Exemestane SanoSwiss 25 mg plėvele dengtos tabletės, Anastrozole Accord 1 mg plėvele dengtos tabletės, Letrozole SanoSwiss 2,5 mg plėvele dengtos tabletės, Tamoxifen EBEWE 20 mg tabletės

    PUMA BIOTECHNOLOGY, INC.

    Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

    phase 2 small molecule active

    1 trial

  23. GGTA1 KO Thymokidney

    United Therapeutics Europe Ltd

    ESRD (End-Stage Renal Disease)

    phase 2 mab active

    1 trial

  24. GT719 Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hematological Malignancy (Leukemia- Lymphoma)

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources